Glenmark Life Sciences Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹82(11.39%)
Premium (ELP)
The public market debut of Glenmark Life Sciences Limited's was completed on Aug 06, 2021 with its listing on the NSE, BSE exchange. The IPO process raised 2,10,22,222 Shares in total capital, consisting of 1,47,22,222 Shares in new equity and ₹454.00 Cr in existing share sales through the OFS route.
The offering featured a price range of ₹695 to ₹720 and minimum application size of 20 shares. Investor response during the subscription period from Jul 27, 2021 to Jul 29, 2021 influenced the final allotment ratios across investor categories.
Final allotment was announced on Aug 03, 2021, distributing shares to successful subscribers. The listing established a continuous market for the company's shares, enabling liquidity, valuation transparency, and broader investor participation.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Incorporated in 2011, Glenmark Life Sciences is a leading manufacturer of active pharmaceutical ingredients (APIs), developing and supplying high-quality products used in treatments for cardiovascular, central nervous system, pain management, diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas. The company serves customers in India and exports its products to several international markets including Europe, North America, Latin America, and Japan. It operates four manufacturing facilities located at Ankleshwar and Dahej in Gujarat, and Mohol and Kurkumbh in Maharashtra, with a total annual installed capacity of 725.8 KL as of December 31, 2020.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Leading API Manufacturer: Specializes in APIs for chronic therapies like CVS, CNS, diabetes, and pain management.
- Global Exports: Supplies products across Europe, Latin America, North America, Japan, and other regions.
- Strong Global Relationships: Works closely with leading generic pharmaceutical companies worldwide.
- Strong Financials: Proven track record of consistent financial performance.
- Quality & R&D Focus: High-quality manufacturing supported by robust R&D infrastructure.
NA
- Glenmark Pharmaceuticals Limited
Glenmark Life Sciences Limited
Kfin Technologies Limited